Compare Novavax Inc (NVAX) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs SkyWest Inc — how do they compare? Novavax Inc trades at $7.9 (market cap $1.31B), while SkyWest Inc trades at $106.37 (market cap $4.19B). The key difference: SkyWest Inc is far larger — about 3.2× Novavax Inc's market cap, and SkyWest Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | SKYW | |
|---|---|---|
Market Cap | $1.31B | $4.19B |
Sector | Health | Technology |
52-Week High | $11.19 | $123.72 |
52-Week Low | $6.22 | $78.40 |
Enterprise Value | $889.30M | $5.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
SkyWest (SKYW) trades at $106.38, down 1.2% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $109.33. The stock shows solid fundamentals with a P/E of 10.72 and ROE of 15.34%, though Q2 2026 earnings missed estimates. Recent news highlights executive stock sales alongside institutional interest and a 7.7% post-earnings rally noted by Zacks Investment Research on 2026-07-27.
The outlook is cautiously positive given analyst buy ratings (56.25%) and undervalued metrics, but risks include fuel cost volatility from Iran war impacts (New York Post, 2026-07-07) and mixed earnings performance. Upside potential exists if Q3 2026 meets its $3.13 EPS expectation, balancing insider selling with buyback support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
